A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities. 

The first FDA-approved pacing lead specifically developed for LBBAP is now being implanted throughout the United States. 

ImmunityBio, the developer of bladder cancer treatment Anktiva, is accused by the U.S. Food and Drug Administration of disseminating “false or misleading information” about the drug's efficacy in an advertisement and podcast. The FDA said it’s not the first time it's sent a warning letter to the company’s executives over allegedly inaccurate claims.

Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations. 

A new acellular tissue-engineered vessel developed by Vascudyne could provide surgeons with a safe, effective alternative to saphenous vein grafts.

Several U.S. medical societies have collaborated on a new report advocating for better safety standards in cardiac catheterization labs. As one cardiologist described it, clinicians have shifted from "accepting risk" to "expecting better."

A new clinical trial investigated the safety and efficacy of the procedure, along with its impact on urinary incontinence, erectile dysfunction and other factors.